Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FP6WR
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,547
Award facts
- Contract value 100% obligated
- $1,547.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,547.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The award, issued on November 6, 2025, with an ultimate completion date of December 1, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with a $499.999 billion ceiling value under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which became effective November 13, 2025, and extends through December 31, 2036.
XOLAIR (omalizumab) is a biologic immunosuppressant utilized in the treatment of severe allergic asthma and chronic idiopathic urticaria, reflecting the specialized pharmaceutical requirements supported through the PPV-G GEN V program. DMS Pharmaceutical Group serves as a critical regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, which enables the DLA to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The contractor has demonstrated substantial federal contracting activity with the DLA Medical Supply Chain division, with no identified subcontractor relationships on this award.
Quick answers
Who was awarded contract SPE2DB26FP6WR?
SPE2DB26FP6WR was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DB26FP6WR worth?
The government has obligated $1,547 on SPE2DB26FP6WR.
Is contract SPE2DB26FP6WR an order under another contract?
Yes. SPE2DB26FP6WR is a delivery order under SPE2DB22D9311, an indefinite delivery contract.
Was contract SPE2DB26FP6WR competed?
The extent of competition for SPE2DB26FP6WR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award